Novartis
EMA waves through a raft of drug recommendations
June 26, 2015Research and Development, Sales and Marketing AbbVie, Alexion, CHMP, EMA, Novartis, Novo Nordisk, brett wells
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended several treatments for marketing …
Lilly and Novartis face legal challenges
June 25, 2015Medical Communications, Sales and Marketing Gleevec, Glivec, Novartis, cymbalta, imatinib, lilly, zyprexa
Judges in California have ruled that Lilly should face claims it failed to fully disclose the extent of post-withdrawal side …
Pfizer acquires meningitis vaccines from GSK
June 23, 2015Sales and Marketing GSK, Mencevax, Nimenrix, Novartis, Pfizer, meningitis
Pharma giants GSK and Pfizer have announced an agreement to transfer the ownership of two meningitis vaccines from GlaxoSmithKline to …
Amgen and Novartis tussle over biosimilar injunction
June 4, 2015Sales and Marketing Amgen, FDA, Neupogen, Novartis
Novartis has begun its court battle with Amgen over its biosimilar of cancer drug Neupogen, which Amgen is trying to …
NICE green-light for Novartis skin drug
May 29, 2015Sales and Marketing Cosentyx, IL-17, NICE, Novartis, Secukinumab
NICE has released positive draft guidance for three treatments, including the first in a new generation of psoriasis drugs. Novartis’ …
Novartis reveals ASCO plans
May 27, 2015Sales and Marketing ASCO, GSK, Novartis
Novartis’ first ASCO conference since buying GlaxoSmithKline’s oncology business will be showcasing drugs from the acquisition. The two firms swapped …
Survey reveals pharma’s most reputable companies
May 14, 2015Medical Communications, Sales and Marketing Novartis, nayer, reputation
Bayer has held on to the top spot in a global survey of how much the general public trusts and …
Novartis invests further into Poland
May 11, 2015Manufacturing and Production, Sales and Marketing Novartis, Poland, Sandoz, manufacturing, packaging
Sandoz the generics division of Novartis has opened a large packaging centre in Stryków in Poland. Valued at 171 million …
US Court blocks Novartis biosimilar Neupogen
May 8, 2015Sales and Marketing Neupogen, Novartis, Zarxio, biosimilar, filagrastim, filgrastim-sndz
Novartis have been temporarily prevented from marketing its biosimilar version of Amgen’s drug Neupogen in the US. Earlier this year …
Boardroom shuffles at GSK and Roche
May 8, 2015Medical Communications, Sales and Marketing GSK, Novartis, Roche, ViiV, changes, leadership
GlaxoSmithKline and Roche have announced the latest changes to its leadership teams as the companies regroup for the year ahead. …
Generics continue to erode GSK sales
May 6, 2015Sales and Marketing GSK, HIV, Novartis, Q1, ViiV, Witty, hampton, respiratory
GlaxoSmithKline’s pharma sales continued to slide in the first quarter of 2015, but ViiV healthcare and the portfolios acquired from …
Novartis and Abbott start year with strong Q1 sales
April 23, 2015Sales and Marketing Abbott, Amgen, Cosentyx, GSK, Neupogen, Novartis, Secukinumab, Zarxio, biosimilar, filgrastim, financials
Novartis and Abbott have both posted strong first-quarter results and made bullish predictions about their financial performance in 2015. Novartis …
Boehringer Ingelheim and Bayer ‘taking the lead’ in social media
April 22, 2015Medical Communications, Sales and Marketing Bayer, Boehringer Ingelheim, J&J and Merck, Novartis, Ogilvy Healthworld
Pharma may be finally embracing social media as a vehicle for engaging with doctors and patients, after posting more than …
Novartis MS drug scores positive late-stage trial result
April 21, 2015Research and Development, Sales and Marketing MS, Novartis, fingolimod, gilenya, multiple sclerosis
People with some of the most common forms of multiple sclerosis (MS) who are treated with Gilenya are less likely …
GSK sees further US job losses following Novartis deal
April 17, 2015Research and Development, Sales and Marketing GSK, Jobs, Novartis, cuts, merger, pittsburgh, restructuring
Hundreds more jobs are at risk within GlaxoSmithKline as the fallout from the company’s asset-swapping deal with Novartis continues. Staff …
Latest content
FibroFind appoints Lee Borthwick as CEO
